Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Charles "Pat" Davis, MD, PhD, is a board certified Emergency Medicine doctor who currently practices as a consultant and staff member for hospitals. He has a PhD in Microbiology (UT at Austin), and the MD (Univ. Texas Medical Branch, Galveston). He is a Clinical Professor (retired) in the Division of Emergency Medicine, UT Health Science Center at San Antonio, and has been the Chief of Emergency Medicine at UT Medical Branch and at UTHSCSA with over 250 publications.
Acetylcholinesterase inhibitors may decrease the effectives of
prochlorperazine. Centrally acting acetylcholinesterase inhibitors may increase
the neurotoxic effects of antipsychotic agents.
Combining prochlorperazine with alcohol,
kava kava, CNS depressants, and
cannabis may increase the risk of CNS depressant side effects.
Antacids may decrease the absorption of prochlorperazine.
Prochlorperazine may cause anticholinergic side effects such as
dry eyes, decreased urinary output, and mental
Combining agents with similar anticholinergic effects increases the risk of
experiencing such adverse events.
Prochlorperazine may increase the blood levels of dofetilide (Tikosyn).
Combination use is not recommended.
Deferoxamine (Desferal) may increase the risk of experiencing side effects of
prochlorperazine treatment. Combination use has resulted in the prolonged loss
Metoclopramide (Reglan) may increase the side effects of antipsychotic
agents. Combination use is not recommended.
Prochlorperazine may increase the CNS depressant effects of orphenadrine (Norflex)
or paraldehyde (Paral). Combination use is not recommended.
Combining prochlorperazine and
potassium chloride may result in an increase
in the ulcerogenic effect of potassium chloride (Klor-Con). Combination use is
generally not recommended.
Combining prochlorperazine with
(Thalomid) may increase the risk of
experiencing CNS depressant side effects. This combination is generally not
PREGNANCY: Prochlorperazine has not been adequately evaluated in pregnant women. Due to the lack of conclusive safety data, prochlorperazine should be
avoided in pregnancy except in cases of severe nausea and vomiting that requires
treatment and potential benefit justifies the potential risk to the fetus.
NURSING MOTHERS: It is not known if prochlorperazine is excreted into human
milk. Other phenothiazines are excreted into breast milk. If clearly needed, prochlorperazine
should be used cautiously in females who are nursing.